

acute respiratory viral infections includes etiotropic, pathogenetic and symptomatic therapy. Etiotropic drugs used for the treatment of acute respiratory viral infections include antiviral drugs (AD). The timely appointment of effective AD in patients with ARVI in most cases can prevent the development of complications and accelerate recovery.

Aim of the study is to calculate and analyze the volumes of consumption of AD on the pharmaceutical market of Ukraine for 2013-2017 years.

Materials and methods. Consumption of AD was estimated using the ATC / DDD methodology recommended by WHO. DDDs /1000/day is used to calculate the consumption of AD.

Results and discussion. Analyzing the results, we can conclude that the leader in consumption during 2013-2017 was inosin pranobex. In the second place, according to the volume of consumption, there are other antiviral drugs, the third and fourth places are taken by the preparations of rimantadine and umifenovir, then oseltamivir and in the last place zanamivir. During the study period, the total consumption of all AD increased and was in units of DDDs/1000/day, respectively, 0.64 (2013); 0.56 (2014); 0.53 (2015); 0.92 (2016); 0.85 (2017). In view of the considerable prevalence of acute respiratory infections in the Ukrainian population, the volume of patients requiring the use of antiviral drugs and the actual volume of patients who have taken one course of treatment for AD were calculated. The analysis showed that a very small proportion of the population (from 0.60% to 0.85%) annually received one 10-day course of treatment with antiviral drugs. The annual volume of patients with acute respiratory viral infections, requiring the use of AD, covers from 21.95% to 23.58% of the population, accounting for 10 million patients with ARVI.

Conclusions. Indicators for the use of AD for the treatment of patients with acute respiratory system infections are very low, which may be due to high cost of treatment, insufficiently proven clinical efficacy and low frequency of appointment.

ASSESSMENT OF CONSUMPTION AND VOLUMES OF REALIZATION OF DRUGS FOR THE ACID RELATED DISEASES TREATMENT IN UKRAINE

Shershnova S. S., Udovichenko M. N.
Scientific supervisor: assoc. prof. Gerasymova O. A.
National University of Pharmacy, Kharkiv, Ukraine
ph-econom@nuph.edu.ua

Introduction. The acid related diseases of the digestive system are common in different age groups of patients in many countries, including Ukraine. Many of them are chronic diseases and require long-term use of medicines. Therefore, drugs for the acid related diseases treatment are among the most popular drugs in gastroenterological practice.

Aim. Determine the assortment, volumes of sales and consumption of drugs for the treatment of acid related diseases in Ukraine in 2016.

Materials and methods. The objects of the study were representatives of the group A02 «Drugs for acid related diseases» (antacids, proton pump inhibitors, H₂-receptor antagonists, combinations for eradication of *Helicobacter pylori*, medicines of the groups «Other drugs for peptic ulcer and gastroesophageal reflux disease» and «Other drugs for acid related diseases».

Methods of marketing research were used in the work to analyze the pharmaceutical market. International non-proprietary names and trade names of representatives of the group A02 «Drugs for acid related diseases» in the pharmaceutical market of Ukraine and the volumes of their sale in physical units in 2016 were determined according to the data of the market research system «Pharmstandard» of the company «Morion».

Volumes and structure of consumption of proton pump inhibitors and H₂-receptor antagonists in Ukraine in 2016 were determined using the ATC/DDD methodology.

Results and discussion. Drugs for the treatment of acid related diseases were presented in Ukraine in 2016 in the amount of 33 international non-proprietary names and 240 trade names. Most of them are representatives of proton pump inhibitors (120 trade names). Combinations for eradication of *Helicobacter*

pylori were presented in the smallest amount (1 trade name). The remaining groups of drugs for the treatment of acid related diseases were present in Ukraine moderately: from 19 to 46 trade names. The number of domestic medicines is 30% (72 drugs). The number of offers on the imported drugs market exceeds the offers of domestic manufacturing companies by almost 2 times.

Drugs of group A02 «Drugs for acid related diseases» were presented in various forms of release: tablets, capsules, gels and suspensions for oral applying, chewable tablets, powders and suspensions for solutions preparation, solutions for injections, vegetal collections, oils. Most of drugs (80%, 192 trade names) were presented in the form of tablets and capsules.

The range of prices of drugs for the treatment of acid related diseases in 2016 in Ukraine was wide: from 3.59 to 1686.68 UAH.

The total volume of sales of drugs for the treatment of acid related diseases in Ukraine in 2016 was 25904448 packages. The largest volumes of sales were established for H₂-receptor antagonists and proton pump inhibitors, the lowest for other drugs for peptic ulcer and gastroesophageal reflux diseases, combinations for eradication of *Helicobacter pylori*. The leaders in the number of sold packages were H₂-receptor antagonist ranitidine, proton pump inhibitor omeprazole and representatives of the group «Other drugs for acid related diseases» - sea buckthorn oil and flax seeds. Their trade names held leading positions in the rankings on the number of sold packages in 2016: «Ranitidine-Zdorovye» (Pharmaceutical company «Zdorovye», table 150 mg N20), «Omez» («Dr. Reddy's», capsules 20 mg N30), «Ranitidin-Darnitsa» in two forms of release (Pharmaceutical Firm «Darnitsa», table 150 mg N20 and table 150 mg N10), «Sea buckthorn oil» («Zhitomir Pharmaceutical Factory», oil, 50 ml), «Omeprazol-Farmak» (Pharmaceutical company «Farmak», capsules 0.02 g N30), Flax seeds (company «Lectravay», seeds 100 g, pack). Most of them were domestic drugs. The leader in the number of sold packages was H₂-receptor antagonist «Ranitidine-Zdorovye» (Pharmaceutical company «Zdorovye», table 150 mg N20). The number of realized packages of this drug was 3384997.

The largest volumes of consumption in terms of DDDs /1000 inhabitants/day in 2016 in Ukraine was established for proton pump inhibitors: 12.48. The consumption of H₂-receptor antagonists was 2.2 times lower (5.55 DDDs/1000 inhabitants/day). The leader in terms of consumption in 2016 among the inhibitors of the proton pump was omeprazole, among the antagonists of H₂-receptor antagonists was ranitidine.

Conclusions. Most drugs of group A02 «Drugs for acid related diseases» was presented in a wide range in Ukraine in 2016 and has a wide range of pack prices. The leaders in volume of saled packages are mainly domestic drugs of H₂-receptor antagonists, proton pump inhibitors and representatives of the group «Other drugs for acid related diseases». The largest volumes of consumption in terms of DDDs/1000 inhabitants/day were established for proton pump inhibitors.

STRUCTURE OF REALIZATION OF ANTIHELMINT MEDICINES IN PHARMACIES OF HARKKOV 2017

Uddu Omar

Scientific supervisor: prof. Bezdetko N. V.

National University of Pharmacy, Kharkiv, Ukraine

Ph-econom@nuph.edu.ua

Introduction. Parasitic diseases rank third in frequency. In the world, 16 million people die every year from parasitic diseases. According to the Ministry of Health, every resident of Ukraine during the life carries a parasitic disease. Helminthiasis are treated with anthelmintic drugs. There are old and new anthelmintic drugs on the market. The price of these drugs is very different

Aim. To determine the structure of sales of anthelmintic medicines in pharmacies and on the pharmaceutical market of Ukraine

Materials and methods. Marketing research of the pharmaceutical market. Retrospective ABC/frequency analysis of the range and volume of drug sales. Research assortment was conducted in 5 pharmacies of the city of Kharkov. Study period – 2017.

Results and discussion. Anthelmintic medicines for the international anatomo-therapeutic classification belong to group P06A. In the analysis of the pharmaceutical market of Ukraine for the last year on the basis of 14 MMN was presented 46 trade names (TN) anthelmintic from 13 countries. The